Holen Sie sich die Stockscreener-App
12.61
0.08%
0.010
Handel nachbörslich:
12.57
-0.04
-0.32%
Schlusskurs vom Vortag:
$12.60
Offen:
$12.67
24-Stunden-Volumen:
3.61M
Relative Volume:
0.67
Marktkapitalisierung:
$1.76B
Einnahmen:
$67.67M
Nettoeinkommen (Verlust:
$-412.69M
KGV:
-3.2954
EPS:
-3.8266
Netto-Cashflow:
$-395.87M
1W Leistung:
+5.61%
1M Leistung:
-7.48%
6M Leistung:
+48.00%
1J Leistung:
+37.66%
1-Tages-Spanne:
$12.24
$12.89
1-Wochen-Bereich:
$11.79
$12.89
52-Wochen-Spanne:
$6.83
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Firmenname
Intellia Therapeutics Inc
Sektor
Branche
Telefon
857-285-6200
Adresse
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
12.61 | 1.76B | 67.67M | -412.69M | -395.87M | -3.8266 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-02 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-11-12 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-11-11 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-11-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-10-28 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2025-10-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-10-06 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-21 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-02-28 | Herabstufung | Goldman | Neutral → Sell |
| 2025-02-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-04-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-03-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-01 | Eingeleitet | Citigroup | Sell |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-06-16 | Eingeleitet | BofA Securities | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-02-18 | Eingeleitet | William Blair | Outperform |
| 2022-02-07 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Eingeleitet | Cowen | Outperform |
| 2022-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2021-10-05 | Eingeleitet | Guggenheim | Buy |
| 2021-09-24 | Eingeleitet | Stifel | Buy |
| 2021-06-28 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-07 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-22 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Eingeleitet | Truist | Buy |
| 2020-10-14 | Eingeleitet | Wells Fargo | Overweight |
| 2020-09-18 | Eingeleitet | Goldman | Buy |
| 2020-02-28 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-11-01 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-10 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-11-02 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-10-29 | Eingeleitet | Credit Suisse | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Mkt Perform |
| 2018-05-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2017-11-01 | Bestätigt | Jefferies | Buy |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-05 | Hochstufung | Jefferies | Hold → Buy |
Alle ansehen
Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten
Avoiding Lag: Real-Time Signals in (NTLA) Movement - Stock Traders Daily
Intellia Therapeutics’ stock rocked by patient death in gene therapy trial - MSN
Chardan Capital Maintains Intellia Therapeutics (NTLA) Buy Recommendation - MSN
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates - Investing News Network
Why is Intellia Therapeutics (NTLA) a Battleground Stock with 38% Short Interest - Kavout
Intellia Drops Counterclaims In Gene-Editing Patent Case - Law360
Intellia Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Intellia Dismisses Four Counterclaims in BlueAllele Patent Suit - Bloomberg Law News
Intellia Therapeutics’ SWOT analysis: gene-editing stock faces regulatory test By Investing.com - Investing.com Nigeria
Intellia Therapeutics’ SWOT analysis: gene-editing stock faces regulatory test - Investing.com
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry? - Yahoo Finance
Does Intellia Therapeutics (NTLA) Cash Runway Truly Offset Dilution Concerns From Its Recent Equity Raise? - Sahm
Buy the Rumor, Sell the News: Intellia (NTLA) Falls After Landmark Phase 3 Win - CoinCentral
Intellia Therapeutics FDA rolling application for gene therapy puts hype to test - MSN
Intellia Therapeutics says its CRISPR-based treatment succeeds in pivotal trial - MSN
NTLA Q1 earnings beat estimates, revenues miss mark, pipeline in focus - MSN
A Look At Intellia Therapeutics (NTLA) Valuation After Recent Gene Editing Trial And BLA Progress - Sahm
Intellia Therapeutics (NTLA) slides as investors digest recent earnings and dilution overhang - Quiver Quantitative
Discipline and Rules-Based Execution in NTLA Response - Stock Traders Daily
Earnings Update: Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st
Intellia Therapeutics, Inc. (NASDAQ:NTLA) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
Intellia Therapeutics (NTLA) Quarterly Loss Near US$96 Million Tests Bullish Profitability Timeline - Sahm
Wells Fargo Remains a Hold on Intellia Therapeutics (NTLA) - The Globe and Mail
NTLA Maintained by Bernstein -- Price Target Raised to $17.00 - GuruFocus
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $15 to $25 - Moomoo
NTLA Maintains by HC Wainwright & Co. -- Price Target Lowered to $25 - GuruFocus
Wedbush Remains a Hold on Intellia Therapeutics (NTLA) - The Globe and Mail
H.C. Wainwright cuts Intellia Therapeutics stock price target to $25 on dilution - Investing.com Australia
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Perspective Therapeutics (CATX) - The Globe and Mail
H.C. Wainwright cuts Intellia Therapeutics stock price target to $25 on dilution By Investing.com - Investing.com South Africa
RBC Capital Keeps Their Hold Rating on Intellia Therapeutics (NTLA) - The Globe and Mail
High Growth Tech Stocks In The US For May 2026 - simplywall.st
NTLA stock rockets after hours before critical data for genetic disorder therapy - MSN
Intellia Therapeutics Price Target Cut to $49.00/Share From $58.00 by Canaccord Genuity - Moomoo
Transcript : Intellia Therapeutics, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 03 - marketscreener.com
Cathie Wood’s ARK sells Twist Bioscience stock, buys Intellia shares - Investing.com
Cathie Wood’s ARK sells Twist Bioscience stock, buys Intellia shares By Investing.com - Investing.com India
Intellia Therapeutics Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Cuts Target Price to $19 - Moomoo
NTLA SEC FilingsIntellia Therape 10-K, 10-Q, 8-K Forms - Stock Titan
NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus - TradingView
NTLA Reiterated by Wedbush -- Price Target Maintained at $12 - GuruFocus
Intellia short interest rises most among biotech stocks in latest periodBaird - Investing.com
Intellia Therapeutics Stock Short Interest Rises to 39.28% - Quiver Quantitative
NTLA jumps premarket on positive late-stage trial data for gene-editing therapy — retail says buy now before it’s too late - MSN
How Investors May Respond To Intellia Therapeutics (NTLA) Raising Capital And Advancing Its CRISPR HAE Therapy - Sahm
symbol__ Stock Quote Price and Forecast - CNN
Intellia Therapeutics Inc earnings beat by $0.10, revenue topped estimates - Investing.com South Africa
NTLA SWOT Analysis: Key Insights from the 10-Q Filing - GuruFocus
$Intellia Therapeutics (NTLA.US)$ Need to drop to 14 bf it take off.. - Moomoo
Intellia Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Finanzdaten der Intellia Therapeutics Inc-Aktie (NTLA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Intellia Therapeutics Inc-Aktie (NTLA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Clark Eliana | EVP, Chief Technical Officer |
Mar 02 '26 |
Sale |
13.78 |
607 |
8,364 |
93,864 |
| LEONARD JOHN M | President and CEO |
Jan 05 '26 |
Sale |
9.21 |
34,146 |
314,485 |
1,013,339 |
| Schultes Birgit C | EVP, Chief Scientific Officer |
Jan 05 '26 |
Sale |
9.21 |
8,508 |
78,359 |
98,533 |
| BASTA JAMES | EVP, General Counsel |
Jan 05 '26 |
Sale |
9.21 |
10,397 |
95,756 |
101,528 |
| Cohen Fred E | Director |
Jan 05 '26 |
Buy |
9.35 |
150,000 |
1,402,500 |
207,453 |
| Lebwohl David | EVP, Chief Medical Officer |
Jan 05 '26 |
Sale |
9.21 |
11,903 |
109,627 |
121,249 |
| Clark Eliana | EVP, Chief Technical Officer |
Jan 05 '26 |
Sale |
9.21 |
9,515 |
87,633 |
87,118 |
| Dulac Edward J III | EVP, Chief Financial Officer |
Jan 05 '26 |
Sale |
9.21 |
6,379 |
58,751 |
99,683 |
| Dube Michael P | VP, Chief Accounting Officer |
Jan 05 '26 |
Sale |
9.21 |
2,989 |
27,529 |
52,277 |
| LEONARD JOHN M | President and CEO |
Dec 11 '25 |
Option Exercise |
6.83 |
49,959 |
341,220 |
1,127,074 |
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):